The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...

新浪财经讯 北京时间2月16日凌晨消息，据国外媒体报道，两名熟知内情的消息人士周二称，赛诺菲安万特(SASY.PA)已经与美国生物技术公司Genzyme Corp ...

法国赛诺菲安万特 SASY.PA 接洽生物技术公司Genzyme Corp GENZ.O 商讨收购事宜,这家法国制药商正寻机进行大规模的收购. 法国赛诺菲安万特 SASY.PA 接洽生物技术公司Genzyme Corp GENZ.O 商讨收购事宜,这家法国制药商正寻机进行大规模的收购. 一场制造业务的危机导致Genzyme ...

Franco-German Aventis (AVEP.PA) has accepted an improved 53.7 billion euros ($63.81 billion) takeover bid from Sanofi-Synthelabo (SASY.PA) in a move creating the world's third-largest drug company ...

PARIS (Reuters) - The boss of drugmaker Sanofi (SASY.PA) Chris Viehbacher could not say on Tuesday if he had the support of his board and confirmed to Reuters that his chairman declined to clarify ...

PARIS (Reuters) - Sanofi (SASY.PA) will step up its push into China, its second biggest market after the United States, in the next five years as part of a wider expansion into emerging countries ...

Feb 3 (Reuters) - Sanofi SASY.PAon Friday forecast moderate earnings growth this year, sayinghigher demand for its bestselling drug Dupixent would be partly offset by competition for multiple ...

FRANKFURT (Reuters) - Boehringer Ingelheim expects negotiations with Sanofi (SASY.PA) about the drugmakers' planned asset swap to be complex but is confident the deal can be wrapped up by the end ...

PARIS, Oct 11 (Reuters) - Healthcare companies Sanofi SASY.PA and partner Regeneron REGN.O presented on Tuesday more positive data for their Dupixent product. The companies said new data showed ...

PARIS (Reuters) - Sanofi (SASY.PA) is drawing up a shortlist of candidates for the post of chief executive to replace Chris Viehbacher, ousted by the board last month, a source close to the French ...

(This Sept 14 story has been refiled to add dropped words in fifth paragraph.) By Matthias Blamont PARIS (Reuters) - Sanofi (SASY.PA) will continue to implement cost savings after having reached a 1.5 ...